|
1
|
Watson D: Rethinking the mood and anxiety
disorders: A quantitative hierarchical model for DSM-V. J Abnorm
Psychol. 114:522–536. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barlow DH: Unraveling the mysteries of
anxiety and its disorders from the perspective of emotion theory.
Am Psychol. 55:1247–1263. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
van Mill JG, Hoogendijk WJ, Vogelzangs N,
van Dyck R and Penninx BW: Insomnia and sleep duration in a large
cohort of patients with major depressive disorder and anxiety
disorders. J Clin Psychiatry. 71:239–246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Uhde TW, Cortese BM and Vedeniapin A:
Anxiety and sleep problems: Emerging concepts and theoretical
treatment implications. Curr Psychiatry Rep. 11:269–276. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Papadimitriou GN and Linkowski P: Sleep
disturbance in anxiety disorders. Int Rev Psychiatry. 17:229–236.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Marcks BA, Weisberg RB, Edelen MO and
Keller MB: The relationship between sleep disturbance and the
course of anxiety disorders in primary care patients. Psychiatry
Res. 178:487–492. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cunnington D, Junge MF and Fernando AT:
Insomnia: Prevalence, consequences and effective treatment. Med J
Aust. 199:S36–S40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hyttel J: Citalopram-pharmacological
profile of a specific serotonin uptake inhibitor with
antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry.
6:277–295. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Jindal RD and Thase ME: Treatment of
insomnia associated with clinical depression. Sleep Med Rev.
8:19–30. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
ShahsavandAnanloo E, Berenji F,
Sadeghniiat K, Alimadadi A, Zahiroddin AR, Tabatabaee M, AbbasiAsl
M and Ghaeli P: Comparing effects of citalopram with fluoxetine on
sleep quality in patients with major depressive disorder. Eur Rev
Med Pharmacol Sci. 17:1155–1161. 2013.PubMed/NCBI
|
|
11
|
Hajak G, Rodenbeck A, Voderholzer U,
Riemann D, Cohrs S, Hohagen F, Berger M and Rüther E: Doxepin in
the treatment of primary insomnia: A placebo-controlled,
double-blind, polysomnographic study. J Clin Psychiatry.
62:453–463. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Weber J, Siddiqui MA, Wagstaff AJ and
McCormack PL: Low-dose doxepin: In the treatment of insomnia. CNS
Drugs. 24:713–720. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buysse DJ, Reynolds CF III, Monk TH,
Berman SR and Kupfer DJ: The Pittsburgh sleep quality index: A new
instrument for psychiatric practice and research. Psychiatry Res.
28:193–213. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hamilton M: The assessment of anxiety
states by rating. Br J Med Psychol. 32:50–55. 1959. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sivertsen B, Krokstad S, Øverland S and
Mykletun A: The epidemiology of insomnia: Associations with
physical and mental health. The HUNT-2 study. J Psychosom Res.
67:109–116. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Taylor DJ, Lichstein KL, Durrence HH,
Reidel BW and Bush AJ: Epidemiology of insomnia, depression and
anxiety. Sleep. 28:1457–1464. 2005.PubMed/NCBI
|
|
17
|
Harvey AG: A cognitive model of insomnia.
Behav Res Ther. 40:869–893. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Monaca C, Boutrel B, Hen R, Hamon M and
Adrien J: 5-HT 1A/1B receptor-mediated effects of the selective
serotonin reuptake inhibitor, citalopram, on sleep: Studies in 5-HT
1A and 5-HT 1B knockout mice. Neuropsychopharmacology. 28:850–856.
2003.PubMed/NCBI
|
|
19
|
VazquezPalacios G, Hernández-González M,
Guevara Pérez MA and Bonilla-Jaime H: Nicotine and fluoxetine
induce arousing effects on sleep-wake cycle in antidepressive
doses: A possible mechanism of antidepressant-like effects of
nicotine. Pharmacol Biochem Behav. 94:503–509. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fava M, McCall WV, Krystal A, Wessel T,
Rubens R, Caron J, Amato D and Roth T: Eszopiclone co-administered
with fluoxetine in patients with insomnia coexisting with major
depressive disorder. Biol Psychiatry. 59:1052–1060. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Roth T, Zorick F, Wittig R, McLenaghan A
and Roehrs T: The effects of doxepin HCl on sleep and depression. J
Clin Psychiatry. 43:366–368. 1982.PubMed/NCBI
|
|
22
|
Krystal AD, Durrence HH, Scharf M,
Jochelson P, Rogowski R, Ludington E and Roth T: Efficacy and
safety of doxepin 1 mg and 3 mg in a 12-week sleep laboratory and
outpatient trial of elderly subjects with chronic primary insomnia.
Sleep. 33:1553–1561. 2010.PubMed/NCBI
|
|
23
|
Roth T, Heith Durrence H, Jochelson P,
Peterson G, Ludington E, Rogowski R, Scharf M and Lankford A:
Efficacy and safety of doxepin 6 mg in a model of transient
insomnia. Sleep Med. 11:843–847. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Krystal AD, Lankford A, Durrence HH,
Ludington E, Jochelson P, Rogowski R and Roth T: Efficacy and
safety of doxepin 3 and 6 mg in a 35-day sleep laboratory trial in
adults with chronic primary insomnia. Sleep. 34:1433–1442.
2011.PubMed/NCBI
|
|
25
|
Haas HL, Sergeeva OA and Selbach O:
Histamine in the nervous system. Physiol Rev. 88:1183–1241. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Goforth HW: Low-dose doxepin for the
treatment of insomnia: Emerging data. Expert Opin Pharmacother.
10:1649–1655. 2009. View Article : Google Scholar : PubMed/NCBI
|
